nuvalent inc - NUVL
NUVL
Close Chg Chg %
123.45 -0.20 -0.16%
Closed Market
123.25
-0.20 (0.16%)
Volume: 7.24M
Last Updated:
Jun 12, 2026, 4:00 PM EDT
Company Overview: nuvalent inc - NUVL
NUVL Key Data
| Open $123.36 | Day Range 123.16 - 123.45 |
| 52 Week Range 71.14 - 123.62 | Market Cap $9.75B |
| Shares Outstanding 79.00M | Public Float 52.21M |
| Beta 1.15 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$6.06 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 3.98M |
NUVL Performance
| 1 Week | 35.51% | ||
| 1 Month | 20.48% | ||
| 3 Months | 25.86% | ||
| 1 Year | 57.53% | ||
| 5 Years | N/A |
NUVL Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
17
Full Ratings ➔
About nuvalent inc - NUVL
Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.
NUVL At a Glance
Nuvalent, Inc.
One Broadway
Cambridge, Massachusetts 02142
| Phone | 1-857-357-7000 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -425,377,000.00 | |
| Sector | Health Technology | Employees | 228 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
NUVL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 6.304 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -14.336 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
NUVL Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,865,688.596 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
NUVL Liquidity
| Current Ratio | 15.273 |
| Quick Ratio | 15.273 |
| Cash Ratio | 15.048 |
NUVL Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -33.305 |
| Return on Equity | -36.70 |
| Return on Total Capital | -34.075 |
| Return on Invested Capital | -36.70 |
NUVL Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Nuvalent Inc - NUVL
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | - | - | - | - |
Sales Growth
| - | - | - | - | - |
Cost of Goods Sold (COGS) incl D&A
| - | - | - | - | - |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| - | - | - | - | - |
Depreciation
| - | - | - | - | - |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| - | - | - | - | - |
Gross Income
| - | - | - | - | - |
Gross Income Growth
| - | - | - | - | - |
Gross Profit Margin
| - | - | - | - | - |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 86.11M | 149.49M | 280.37M | 414.31M | |
Research & Development
| 63.73M | 113.24M | 217.77M | 306.97M | |
Other SG&A
| 22.38M | 36.25M | 62.59M | 107.34M | |
SGA Growth
| +87.94% | +73.61% | +87.55% | +47.77% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | 17.94M | 55.22M | - |
EBIT after Unusual Expense
| (86.11M) | (149.49M) | (298.31M) | (469.53M) | |
Non Operating Income/Expense
| 4.25M | 23.27M | 38.32M | 44.73M | |
Non-Operating Interest Income
| - | 4.25M | 23.27M | 38.32M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (81.85M) | (126.22M) | (259.99M) | (424.79M) | |
Pretax Income Growth
| -76.65% | -54.20% | -105.98% | -63.39% | |
Pretax Margin
| - | - | - | - | - |
Income Tax
| - | - | 764.00K | 585.00K | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (81.85M) | (126.22M) | (260.76M) | (425.38M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (81.85M) | (126.22M) | (260.76M) | (425.38M) | |
Net Income Growth
| -76.65% | -54.20% | -106.59% | -63.13% | |
Net Margin Growth
| - | - | - | - | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (81.85M) | (126.22M) | (260.76M) | (425.38M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (81.85M) | (126.22M) | (260.76M) | (425.38M) | |
EPS (Basic)
| -1.648 | -2.1678 | -3.9265 | -5.8522 | |
EPS (Basic) Growth
| -71.77% | -31.54% | -81.13% | -49.04% | |
Basic Shares Outstanding
| 49.67M | 58.22M | 66.41M | 72.69M | |
EPS (Diluted)
| -1.648 | -2.1678 | -3.9265 | -5.8522 | |
EPS (Diluted) Growth
| -71.77% | -31.54% | -81.13% | -49.04% | |
Diluted Shares Outstanding
| 49.67M | 58.22M | 66.41M | 72.69M | |
EBITDA
| (86.11M) | (149.49M) | (280.37M) | (414.31M) | |
EBITDA Growth
| -87.94% | -73.61% | -87.55% | -47.77% | |
EBITDA Margin
| - | - | - | - | - |
Snapshot
| Average Recommendation | HOLD | Average Target Price | 131.125 | |
| Number of Ratings | 17 | Current Quarters Estimate | -1.413 | |
| FY Report Date | 06 / 2026 | Current Year's Estimate | -5.647 | |
| Last Quarter’s Earnings | -1.39 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -5.85 | Next Fiscal Year Estimate | -4.354 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 15 | 15 | 17 | 17 |
| Mean Estimate | -1.41 | -1.44 | -5.65 | -4.35 |
| High Estimates | -1.22 | -1.23 | -4.73 | -2.62 |
| Low Estimate | -1.56 | -1.59 | -6.37 | -6.83 |
| Coefficient of Variance | -5.60 | -6.99 | -7.27 | -28.12 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 1 | 16 | 16 |
| OVERWEIGHT | 1 | 4 | 3 |
| HOLD | 15 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Hold | Buy | Buy |
SEC Filings for Nuvalent Inc - NUVL
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Nuvalent Inc - NUVL
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Apr 9, 2026 | James R. Porter President and CEO; Director | 338,593 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $18.93 per share | 6,409,565.49 |
| Apr 9, 2026 | James R. Porter President and CEO; Director | 354,879 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $27.85 per share | 9,883,380.15 |
| Apr 9, 2026 | James R. Porter President and CEO; Director | 343,525 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $103.21 per share | 35,455,215.25 |
| Apr 9, 2026 | James R. Porter President and CEO; Director | 331,100 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $103.78 per share | 34,361,558.00 |
| Apr 9, 2026 | James R. Porter President and CEO; Director | 324,979 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $104.78 per share | 34,051,299.62 |
| Apr 9, 2026 | James R. Porter President and CEO; Director | 324,879 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $105.6 per share | 34,307,222.40 |
| Apr 9, 2026 | James R. Porter President and CEO; Director | 208,686 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 9, 2026 | James R. Porter President and CEO; Director | 131,494 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 3, 2026 | Deborah Miller Chief Legal Officer | 65,134 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $6.89 per share | 448,773.26 |
| Mar 3, 2026 | Deborah Miller Chief Legal Officer | 62,436 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $102.64 per share | 6,408,431.04 |
| Mar 3, 2026 | Deborah Miller Chief Legal Officer | 59,834 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $103.41 per share | 6,187,433.94 |
| Mar 3, 2026 | Deborah Miller Chief Legal Officer | 59,634 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $103.96 per share | 6,199,550.64 |
| Mar 3, 2026 | Deborah Miller Chief Legal Officer | 89,108 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Dec 12, 2025 | Ron Squarer Director | 2,837 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Dec 12, 2025 | Ron Squarer Director | 4,418 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |